Drug intelligence / Profile preview

GMA312

Development stage: Preclinical
Lead developer: Gmax Biopharm
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

GMA312 is a preclinical-stage biologic candidate being developed by Gmax Biopharm for the treatment of pre-eclampsia. Gmax Biopharm specializes in the discovery and engineering of therapeutic monoclonal antibodies and antibody-fusion proteins targeting G-protein coupled receptors (GPCRs). GMA312 is designed to target the underlying vascular and hypertensive pathology of pre-eclampsia, a serious pregnancy complication characterized by high blood pressure and organ damage.

Beyond the preview

Go deeper on GMA312.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GMA312.

Explore the full profile